Stock fact sheet · data as of
ANI Pharmaceuticals, Inc. (ANIP): fair value, margin of safety and Wheel Score
Healthcare · Drug Manufacturers - Specialty & Generic · United States · High Growth
Is ANIP undervalued?
ANIP has a margin of safety of 70%: the stock closed at 72.28 on 16 Oct 2026 against a GLS average fair value of 243.25. 5 of the 8 valuation models that produced a number sit above the price. Our screens treat a discount this large as a strong starting point for a cash-secured put, not as a verdict - the fair value is a model output, and a wide gap can mean the models are missing something the market knows.
The 8 models disagree widely: Lynch gives 46.47 while DCF gives 859.62. A spread that wide means the average is sensitive to which methods you trust; the model table below shows where each one lands, and the Quote page lets you switch any of them off.
The nightly engine files ANIP under High Growth: revenue and earnings growing fast enough that the growth-based models carry the valuation.
Nine valuation models for ANIP
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 859.62 | +1089% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | 56.36 | -22% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 132.44 | +83% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 46.47 | -36% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 306.21 | +324% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 190.90 | +164% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 298.40 | +313% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 55.57 | -23% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | -6.38 | -109% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 99.50 | +38% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
On financial health ANIP scores 7/9 (Piotroski): most of the nine tests - positive earnings and cash flow, falling debt, rising margins and turnover - are passed, which is the kind of balance sheet a wheel trader is happy to be assigned. The GLS Moat score is low at 3.6 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.
Returns on capital are moderate - ROIC 9.0%, ROE 14.5%, ROA 5.4% - with debt at 0.60 times equity and a free-cash-flow yield of 9.6%.
ANI Pharmaceuticals, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Sales of rare disease pharmaceutical pr… 92%, Sales of Established Brands 8% (quarter Q2 FY2026).
Institutional ownership scores 10/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 7 / 9 | ROIC | 9.0% |
|---|---|---|---|
| GLS Moat | 3.6 / 10 | ROE | 14.5% |
| Debt / equity | 0.60 | ROA | 5.4% |
| Free-cash-flow yield | 9.6% | Payout ratio | 0% |
| Institutions | 10 / 10 | Insiders · Congress | 1 · 5 / 10 |
Wheel Score 77: Good
ANIP scores 77 out of 100 on the Wheel Score (Good band, 65-79). The score blends the margin of safety (Value, 25/25), Piotroski health (16/20), the GLS moat (5/15), the option premium on offer (20/20) and how easily the stock trades (11/20). Moat (5/15) is the part holding the score back.
Implied volatility is 47% on the near-the-money contracts 20-60 days out - inside the 35-60% range the Wheel Score pays full marks for: enough premium to be worth selling, not so much that the risk is unpaid. Chain open interest is 5,769 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 241k shares a day on a market cap of $1.7B, with a beta of 0.49 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 11 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 70% margin of safety | |
| Health | 16 / 20 | Piotroski 7/9 | |
| Moat | 5 / 15 | moat 3.6/10 | |
| Premium | 20 / 20 | implied volatility 47% | |
| Stability | 11 / 20 | 241k shares/day, $1.7B cap, beta 0.49 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 6 Nov 2026 (before the open), 21 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Drug Manufacturers - Specialty & Generic
The 12 companies below are the closest to ANI Pharmaceuticals, Inc. by market cap within the Drug Manufacturers - Specialty & Generic industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| TRLV Trulieve Cannabis Corp. | 9.97 | 27.65 | +64% | 45Weak | $1.7B |
| PAHC Phibro Animal Health Corporation | 37.93 | 43.87 | +14% | 72Good | $1.5B |
| ETON Eton Pharmaceuticals, Inc. | 51.33 | 15.29 | -236% | 52Fair | $1.5B |
| ALVO Alvotech | 5.31 | - | - | 33No options | $1.9B |
| PCRX Pacira BioSciences, Inc. | 36.40 | 39.44 | +8% | 63Fair | $1.5B |
| PRGO Perrigo Company plc | 15.95 | 37.60 | +58% | 45Weak | $2.2B |
| CRON Cronos Group Inc. | 3.20 | 2.96 | -8% | 58Fair | $1.2B |
| SUPN Supernus Pharmaceuticals, Inc. | 40.18 | 46.46 | +14% | 45Weak | $2.3B |
| BHC Bausch Health Companies Inc. | 6.31 | 134.93 | +95% | 45Weak | $2.4B |
| HCM HUTCHMED (China) Limited | 13.94 | 2.93 | -376% | 42Weak | $2.4B |
| AMPH Amphastar Pharmaceuticals, Inc. | 26.42 | 45.40 | +42% | 77Good | $1.1B |
| HROW Harrow Health, Inc. | 28.75 | 4.96 | -480% | 42Weak | $1.1B |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about ANIP
Is ANIP undervalued right now?
By the GLS models, yes: at 72.28 the stock is 70% below the average fair value of 243.25 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of ANIP and what does it mean?
ANIP scores 77 out of 100 (Good). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for ANIP?
243.25 per share as of 16 Oct 2026 - the simple average of the 8 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does ANI Pharmaceuticals, Inc. report earnings next?
The next earnings report is due on 6 Nov 2026 (before the open), 21 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does ANIP have listed options, and how liquid are they?
Yes. The nightly snapshot found 168 listed contracts with 5,769 open interest across all expiries and implied volatility of 47% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.